Early-career investigators in thoracic oncology are invited to apply for LCFA/IASLC grants supporting translational clinical-oncology research with near-term impact on lung cancer care. Projects may span early detection, molecular diagnostics, risk assessment, therapy selection, minimizing toxicity, and improving outcomes in early-stage or metastatic disease. Special consideration is given to studies poised for rapid clinical translation, benefiting underrepresented populations, or improving access to care.
Eligibility Criteria:
-
IASLC membership required and must be maintained throughout the grant term.
-
Doctoral degree (PhD, MD, DO, PharmD, ScD or equivalent).
-
Academic rank at Instructor, Assistant Professor, or Associate Professor (full professors not eligible).
-
No current/previous LCFA grant.
-
May not hold an independent R21, R01, DOD (or comparable) award; not a PI/Co-I on NIH multi-component P/U series; not a PI of a peer-reviewed grant ≥$125,000 direct costs/year for ≥3 years from listed peer-review organizations (mentored K-type or similar career awards are allowed).
-
Physicians: within 7 years of completing residency/fellowship.
-
Laboratory scientists: within 7 years of completing postdoc.
-
Exceptions to the 7-year window may be granted for documented career interruptions (request prior to submission).
-
Institutional commitment of ~50% professional effort to research for the applicant.
-
Investigators with tobacco-industry funding are ineligible.
Funding Details:
-
$100,000 per year for up to 2 years; Year 2 contingent on satisfactory progress and available funds.
-
Up to 50% of the budget may be used for applicant salary and fringe.
-
No indirect costs allowed.
-
No permanent equipment purchases allowed.
-
Maximum travel allocation: $1,000 per year.
-
Grants are awarded to individuals (not transferrable); budget changes require prior approval.
-
Human subjects projects must provide IRB approval and consent forms by grant notification.
Deadline:
- Application deadline posted on the IASLC online portal.
-
Peer-review outcomes communicated by May 15, 2026.
-
Anticipated start date on or around July 1, 2026.
Where to Go For Further Information:
- Program details.
- Direct questions to [email protected].